These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 17010585)

  • 21. Molecular approaches for new vaccines against allergy.
    Niederberger V; Valenta R
    Expert Rev Vaccines; 2006 Feb; 5(1):103-10. PubMed ID: 16451112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological mechanisms of allergen-specific immunotherapy.
    Larché M; Akdis CA; Valenta R
    Nat Rev Immunol; 2006 Oct; 6(10):761-71. PubMed ID: 16998509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvants and vector systems for allergy vaccines.
    Moingeon P; Lombardi V; Saint-Lu N; Tourdot S; Bodo V; Mascarell L
    Immunol Allergy Clin North Am; 2011 May; 31(2):407-19, xii. PubMed ID: 21530828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel immunotherapy vaccine development.
    Jutel M; Akdis CA
    Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):557-63. PubMed ID: 25304230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRNA vaccination as a safe approach for specific protection from type I allergy.
    Weiss R; Scheiblhofer S; Roesler E; Weinberger E; Thalhamer J
    Expert Rev Vaccines; 2012 Jan; 11(1):55-67. PubMed ID: 22149709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA vaccines for the prevention and treatment of allergy.
    Chua KY; Kuo IC; Huang CH
    Curr Opin Allergy Clin Immunol; 2009 Feb; 9(1):50-4. PubMed ID: 19532092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies.
    Brennan FR; Dougan G
    Vaccine; 2005 May; 23(24):3210-22. PubMed ID: 15837222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific immunotherapy in pollen allergy.
    Wallner M; Briza P; Thalhamer J; Ferreira F
    Curr Opin Mol Ther; 2007 Apr; 9(2):160-7. PubMed ID: 17458170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current developments for improving efficacy of allergy vaccines.
    Sandrini A; Rolland JM; O'Hehir RE
    Expert Rev Vaccines; 2015; 14(8):1073-87. PubMed ID: 26013124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases.
    Edlmayr J; Niespodziana K; Focke-Tejkl M; Linhart B; Valenta R
    Curr Top Microbiol Immunol; 2011; 352():121-40. PubMed ID: 21626347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma.
    Bahceciler NN; Ozdemir C; Barlan IB
    Curr Med Chem; 2007; 14(3):265-9. PubMed ID: 17305531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy: what lies beyond.
    Casale TB; Stokes JR
    J Allergy Clin Immunol; 2014 Mar; 133(3):612-9: quiz 620. PubMed ID: 24581428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory treatment strategies for allergic diseases.
    Varga EM; Nouri-Aria K; Till SJ; Durham SR
    Curr Drug Targets Inflamm Allergy; 2003 Mar; 2(1):31-46. PubMed ID: 14561174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1.
    Edlmayr J; Niespodziana K; Linhart B; Focke-Tejkl M; Westritschnig K; Scheiblhofer S; Stoecklinger A; Kneidinger M; Valent P; Campana R; Thalhamer J; Popow-Kraupp T; Valenta R
    J Immunol; 2009 May; 182(10):6298-306. PubMed ID: 19414783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental forms of allergen immunotherapy with modified allergens and adjuvants.
    Mohapatra SS; San-Juan-Vergara H; Wopfner N; Ferreira F
    Clin Allergy Immunol; 2008; 21():393-413. PubMed ID: 18828519
    [No Abstract]   [Full Text] [Related]  

  • 36. Standardization of allergen-specific immunotherapy vaccines.
    Spangfort MD; Larsen JN
    Immunol Allergy Clin North Am; 2006 May; 26(2):191-206, v-vi. PubMed ID: 16701140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allergy vaccines: dreams and reality.
    Crameri R
    Expert Rev Vaccines; 2007 Dec; 6(6):991-9. PubMed ID: 18377361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hitting the mucosal road in tolerance induction.
    Wiedermann U
    Nestle Nutr Workshop Ser Pediatr Program; 2009; 64():63-72; discussion 72-74, 251-7. PubMed ID: 19710515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide and Recombinant Allergen Vaccines for Food Allergy.
    Cook QS; Burks AW
    Clin Rev Allergy Immunol; 2018 Oct; 55(2):162-171. PubMed ID: 29368278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies.
    Cromwell O; Fiebig H; Suck R; Kahlert H; Nandy A; Kettner J; Narkus A
    Immunol Allergy Clin North Am; 2006 May; 26(2):261-81, vii. PubMed ID: 16701144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.